Insys Therapeutics Inc (NASDAQ:INSY) had its target price cut by research analysts at Jefferies Group LLC from $16.00 to $14.00 in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 34.36% from the stock’s previous close.
Several other equities research analysts also recently issued reports on INSY. Royal Bank of Canada restated a “buy” rating and set a $23.00 price objective on shares of Insys Therapeutics in a report on Friday, December 9th. Zacks Investment Research upgraded Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 4th. Finally, Oppenheimer Holdings Inc. reiterated a “” rating on shares of Insys Therapeutics in a research report on Thursday, January 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $18.00.
Insys Therapeutics (NASDAQ:INSY) traded down 2.50% on Tuesday, hitting $10.16. 220,661 shares of the stock were exchanged. The stock’s 50 day moving average price is $10.72 and its 200 day moving average price is $10.94. Insys Therapeutics has a 52-week low of $8.70 and a 52-week high of $19.96. The firm has a market cap of $731.08 million, a PE ratio of 101.60 and a beta of 0.26.
Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings data on Monday, April 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter. Insys Therapeutics had a return on equity of 9.39% and a net margin of 8.71%. The company had revenue of $54.86 million for the quarter, compared to the consensus estimate of $52.08 million. During the same period in the previous year, the business earned $0.42 EPS. Insys Therapeutics’s revenue for the quarter was down 41.6% compared to the same quarter last year. Equities research analysts forecast that Insys Therapeutics will post ($0.34) earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Menora Mivtachim Holdings LTD. bought a new position in Insys Therapeutics during the fourth quarter worth about $119,000. Stevens Capital Management LP acquired a new stake in shares of Insys Therapeutics during the third quarter valued at $147,000. Bank of Montreal Can increased its stake in shares of Insys Therapeutics by 215.3% in the first quarter. Bank of Montreal Can now owns 20,812 shares of the specialty pharmaceutical company’s stock valued at $219,000 after buying an additional 14,212 shares during the last quarter. Acrospire Investment Management LLC increased its stake in shares of Insys Therapeutics by 49.1% in the third quarter. Acrospire Investment Management LLC now owns 25,495 shares of the specialty pharmaceutical company’s stock valued at $301,000 after buying an additional 8,400 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in shares of Insys Therapeutics by 34.9% in the third quarter. Alps Advisors Inc. now owns 30,275 shares of the specialty pharmaceutical company’s stock valued at $357,000 after buying an additional 7,826 shares during the last quarter. Institutional investors own 45.21% of the company’s stock.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.